Phase 1 Trial Featuring First shRNA-Edited CAR-T Therapy to Begin
FDA approves allogenic CAR T cells targeted at BCMA for phase 1 trial in relapsed/refractory multiple myeloma.
Multiple Myeloma
MULTIPLE MYELOMA ADVISOR
FEATURED CONTENT
-
-
COVID-19: Rates of Hospitalization and Mortality Among Patients With Multiple Myeloma
Researchers at a single center in New York City reported on the various factors associated with poor outcomes after infection with SARS-CoV-2. -
How Patients Lose Their Own Voices: Disparities in Patient-Reported Outcome Capture in Clinical Trials
It remains important to interrogate how structural discrimination influences the collection of patient-reported outcomes. -
New Class of Drug Appears to Extend Survival in Patients With Triple-Refractory Multiple Myeloma
Oncopeptides will seek accelerated approval from the FDA after melflufen demonstrates a manageable safety profile. -
Researchers Reveal Racial Disparities in Access to Remdesivir for Patients With Cancer and COVID-19
Black patients were half as likely to receive remdesivir as White patients, according to researchers from the CCC19.
VIDEO SERIES
MULTIPLE MYELOMA NEWS
Rapid Third-Infusion Protocol of Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma
Multiple Myeloma: More Real-World Data Needed To Confirm Effectiveness of New Treatments
Outcomes After Daratumumab Addition to Induction Therapy in Newly Diagnosed Multiple Myeloma
European Myeloma Network Provides Vaccine Recommendations for MM
Gain in Chromosome 1q Should Be Considered High Risk in Myeloma
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Multiple Myeloma
